14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
REGN vs BNTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over BioNTech SE American Depositary Share (BNTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). REGN carries a Unified Composite Score of 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin), whereas BNTX carries 43.3/100 (HOLD) at $81.38 (7.0x Forward P/E, -55.5% operating margin).
Composite vs. Pillar Nuance: While BNTX currently prints a higher short-term Unified Composite Score (43.3/100 HOLD vs. REGN 42.6/100 HOLD), REGN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (30.4% vs. -55.5% operating margin) and revenue trajectory (+36.3% vs. -15.1% YoY).
Technical & Structure Timing Caution: REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.9); meanwhile BNTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REGN vs BNTX. Trailing 12-month operating profitability (REGN 30.4% vs BNTX -55.5%) and valuation multiples (REGN 14.9x vs BNTX 7.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $20.6B market capitalization and -55.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ REGN vs BNTX Key Questions & Quantitative Answers
As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over BioNTech SE American Depositary Share (BNTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). REGN carries a Unified Composite Score of 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin), whereas BNTX carries 43.3/100 (HOLD) at $81.38 (7.0x Forward P/E, -55.5% operating margin). Composite vs. Pillar Nuance: While BNTX currently prints a higher short-term Unified Composite Score (43.3/100 HOLD vs. REGN 42.6/100 HOLD), REGN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (30.4% vs. -55.5% operating margin) and revenue trajectory (+36.3% vs. -15.1% YoY). Technical & Structure Timing Caution: REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.9); meanwhile BNTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
REGN leads the Growth & Scale pillar: REGN posts +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin), compared with BNTX at -15.1% YoY revenue growth and -43.2% YoY earnings growth on $2.42B TTM revenue (76.7% gross margin, -55.5% operating margin). On trailing 12-month operating scale, REGN generates $16.9B in USD-normalized revenue versus $2.42B for BNTX. In operating R&D and SG&A reinvestment, REGN deploys 16.3% of Rev ($2.75B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BNTX.
BNTX screens cheaper on headline valuation multiples. REGN trades at 14.9x Forward P/E, 20.9x Trailing P/E, 1.15x PEG, and 5.7x EV/Revenue (21.5% FCF margin), whereas BNTX trades at 7.0x Forward P/E, 7.0x Trailing P/E, 0.05x PEG, and 8.5x EV/Revenue (-42.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REGN (14.9% ROE) versus BNTX (-8.1% ROE) capital efficiency.
In options market volatility and institutional positioning, REGN carries 35.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 55% Vol realized risk). By comparison, BNTX carries 41.9% implied volatility (76th %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 31% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.